Progress Towards the Development of Anti-Inflammatory Inhibitors of IKKβ

Author(s): Paul Bamborough, James F. Callahan, John A. Christopher, Jeffrey K. Kerns, John Liddle, David D. Miller, Mary A. Morse, William L. Rumsey, Rick Williamson

Journal Name: Current Topics in Medicinal Chemistry

Volume 9 , Issue 7 , 2009

Become EABM
Become Reviewer


The IκB kinases (IKKs) are essential components of the signaling pathway by which the NF-κB p50/RelA transcription factor is activated in response to pro-inflammatory stimuli such as lipopolysaccharide (LPS) and tumor necrosis factor (TNFα). NF-κB signaling results in the expression of numerous genes involved in innate and adaptive immune responses. The pathway is also implicated in chronic inflammatory disorders including rheumatoid arthritis (RA), chronic obstructive pulmonary disorder (COPD), and asthma. Inhibition of the kinase activity of the IKKs is therefore a promising mechanism for intervention in these diseases. Here, we will review the literature describing small molecule inhibitors of IKKβ (IKK2), the most widely studied of the IKKs.

Keywords: I-kappa B kinase inhibitors, IKK, IKKβ, NF-κB, inflammation

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [623 - 639]
Pages: 17
DOI: 10.2174/156802609789007336
Price: $65

Article Metrics

PDF: 15